Table 5.
Beta (β)-HPV DNA prevalence detected on the surface of other EGL cases and the normal genital skin of other EGL cases and controls, at the time of lesion detection (index visit), 6, and 12 months prior to lesion detection
| HPV species/type | Controls n=38 |
Other EGLa n=19 |
|||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Normal genital skin | Normal genital skin | Other EGL | |||||
|
|
|
|
|||||
| 12mo prior | 6mo prior | Index visit | 12mo prior | 6mo prior | Index visit | Index visit | |
|
|
|
|
|||||
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
| Any β-HPV type | 32 (84.2) | 34 (89.5) | 34 (89.5) | 17 (89.5) | 16 (84.2) | 16 (84.2) | 13 (68.4) |
| β1 | |||||||
| Any β1 | 28 (73.7) | 28 (73.7) | 27 (73.0) | 14 (73.7) | 14 (77.8) | 12 (70.6) | 9 (47.4) |
| HPV5 | 10 (26.3) | 11 (28.9) | 6 (16.2) | 5 (26.3) | 5 (27.8) | 4 (23.5) | 4 (21.1) |
| HPV8 | 8 (21.1) | 7 (18.4) | 9 (24.3) | 3 (15.8) | 3 (16.7) | 3 (17.6) | 1 (5.3) |
| HPV12 | 8 (21.1) | 8 (21.1) | 10 (27.0) | 6 (31.6) | 7 (38.9) | 5 (29.4) | 4 (21.1) |
| HPV14 | 3 (7.9) | 5 (13.2) | 5 (13.5) | 5 (26.3) | 3 (16.7) | 0 (0) | 0 (0) |
| HPV19 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| HPV20 | 0 (0) | 0 (0) | 0 (0) | 2 (10.5) | 3 (16.7) | 3 (17.6) | 1 (5.3) |
| HPV21 | 2 (5.3) | 6 (15.8) | 4 (10.8) | 1 (5.3) | 1 (5.6) | 1 (5.9) | 2 (10.5) |
| HPV24 | 14 (36.8) | 9 (23.7) | 13 (35.1) | 8 (42.1) | 8 (44.4) | 8 (47.1) | 1 (5.3) |
| HPV25 | 2 (5.3) | 1 (2.6) | 1 (2.7) | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) |
| HPV36 | 4 (10.5) | 7 (18.4) | 4 (10.8) | 2 (10.5) | 3 (16.7) | 1 (5.9) | 2 (10.5) |
| HPV47 | 13 (34.2) | 10 (26.3) | 12 (32.4) | 1 (5.3) | 2 (11.1) | 5 (29.4) | 1 (5.3) |
| HPV93 | 0 (0) | 0 (0) | 1 (2.7) | 1 (5.3) | 1 (5.6) | 0 (0) | 1 (5.3) |
| β2 | |||||||
| Any β2 | 15 (39.5) | 17 (44.7) | 18 (48.6) | 16 (84.2) | 13 (72.2) | 8 (47.1) | 5 (26.3) |
| HPV9 | 2 (5.3) | 2 (5.3) | 2 (5.4) | 5 (26.3) | 1 (5.6) | 2 (11.8) | 2 (10.5) |
| HPV15 | 2 (5.3) | 1 (2.6) | 1 (2.7) | 1 (5.3) | 2 (11.1) | 1 (5.9) | 0 (0) |
| HPV17 | 4 (10.5) | 6 (15.8) | 4 (10.8) | 5 (26.3) | 5 (27.8) | 3 (17.6) | 2 (10.5) |
| HPV22 | 5 (13.2) | 7 (18.4) | 7 (18.9) | 4 (21.1) | 5 (27.8) | 3 (17.6) | 3 (15.8) |
| HPV23 | 6 (15.8) | 7 (18.4) | 6 (16.2) | 6 (31.6) | 4 (22.2) | 1 (5.9) | 1 (5.3) |
| HPV37 | 0 (0) | 0 (0) | 0 (0) | 3 (15.8) | 1 (5.6) | 2 (11.8) | 1 (5.3) |
| HPV38 | 3 (7.9) | 4 (10.5) | 3 (8.1) | 7 (36.8) | 4 (22.2) | 1 (5.9) | 3 (15.8) |
| HPV80 | 3 (7.9) | 4 (10.5) | 4 (10.8) | 3 (15.8) | 3 (16.7) | 2 (11.8) | 1 (5.3) |
| β3 | |||||||
| Any β3 | 1 (2.6) | 1 (2.6) | 1 (2.7) | 6 (31.6) | 5 (27.8) | 1 (5.9) | 2 (10.5) |
| HPV49 | 1 (2.6) | 0 (0) | 1 (2.7) | 2 (10.5) | 3 (16.7) | 0 (0) | 1 (5.3) |
| HPV75 | 0 (0) | 1 (2.6) | 0 (0) | 4 (21.1) | 3 (16.7) | 0 (0) | 2 (10.5) |
| HPV76 | 0 (0) | 0 (0) | 0 (0) | 4 (21.1) | 1 (5.6) | 1 (5.9) | 0 (0) |
| β4 | |||||||
| HPV92 | 2 (5.3) | 2 (5.3) | 2 (5.4) | 1 (5.3) | 1 (5.6) | 1 (5.9) | 0 (0) |
| β5 | |||||||
| HPV96 | 2 (5.3) | 1 (2.6) | 3 (8.1) | 4 (21.1) | 3 (16.7) | 1 (5.9) | 3 (15.8) |
| Multiple β-HPV types | |||||||
| ≥2 types | 21 (55.3) | 23 (60.5) | 24 (63.2) | 15 (78.9) | 13 (68.4) | 8 (42.1) | 6 (31.6) |
Note: Sample sizes change depending on specimen availability and validity of HPV results.
a
Includes various skin conditions thought to be unrelated to HPV infection, such as seborrheic keratosis and skin tags.